Show simple item record

dc.contributor.authorUusitalo, Hannu
dc.contributor.authorEgorov, Evjeniy
dc.contributor.authorKaarniranta, Kai
dc.contributor.authorAstakhov, Yuri
dc.contributor.authorRopo, Auli
dc.date.accessioned2017-01-19T18:25:18Z
dc.date.available2017-01-19T18:25:18Z
dc.date.issued2016
dc.identifier10.2147/OPTH.S91402fi_FI
dc.identifier.issn1177-5483
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/221
dc.descriptionArticle
dc.description.abstractIntroduction: Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface disease while using preserved latanoprost eye drops benefited from switching to preservative-free tafluprost eye drops. Patients and methods: The analysis was based on 339 glaucoma patients enrolled in two Phase IIIb trials. The patients were required to have two symptoms, or one sign and one symptom of ocular surface disease at baseline, and at least 6 months preceding treatment with latanoprost eye drops preserved with benzalkonium chloride. All eligible patients were switched from latanoprost to preservative-free tafluprost for a total of 12 weeks. Ocular symptoms and ocular signs were evaluated at baseline and at 2 weeks, 6 weeks, and 12 weeks after commencing treatment with tafluprost. Intraocular pressure (IOP), drop discomfort, and treatment preference were evaluated to investigate the clinical efficacy and patient-related outcomes. Results: After 12 weeks of treatment with preservative-free tafluprost, the incidences of irritation/burning/stinging, foreign body sensation, tearing, itching, and dry eye sensation had diminished to one-third of those reported for preserved latanoprost at baseline. The incidences of blepharitis and corneal/conjunctival fluorescein staining had in turn decreased to one-half of those reported for preserved latanoprost. Severity of conjunctival hyperemia was halved during treatment with preservative-free tafluprost, and there was significant improvement in tear break-up time and tear production. A further reduction in IOP (~1 mmHg) was seen with preservative-free tafluprost compared with preserved latanoprost. Drop discomfort was alleviated during preservative-free tafluprost treatment, and an outstanding majority of patients (72%) preferred preservative-free tafluprost over preserved latanoprost. Conclusion: This meta-analysis confirmed that IOP remained at the same level after replacing benzalkonium chloride-preserved latanoprost eye drops with preservative-free tafluprost eye drops. Preservative-free tafluprost significantly decreased the symptoms and signs of ocular surface disease and outrated latanoprost in drop comfort and treatment preference.fi_FI
dc.language.isoENfi_FI
dc.publisherDove Medical Press Ltd.fi_FI
dc.relation.ispartofseriesClinical Ophthalmology
dc.relation.urihttp://doi.org/10.2147/OPTH.S91402fi_FI
dc.rightsCC BY-NC http://creativecommons.org/licenses/by-nc/3.0/
dc.subjectTaflotan®fi_FI
dc.subjectpreserved latanoprostfi_FI
dc.subjectXalatan®fi_FI
dc.subjectocular surface diseasefi_FI
dc.subjectocular symptoms and signsfi_FI
dc.subjectIOPfi_FI
dc.subjectpatient-related outcomefi_FI
dc.titleBenefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsfi_FI
dc.typehttp://purl.org/eprint/type/JournalArticle
dc.description.versionpublisher's pdffi_FI
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id41515743
eprint.statushttp://purl.org/eprint/status/PeerReviewedfi_FI
dc.type.publicationinfo:eu-repo/semantics/article
dc.rights.accessrights© Authors
dc.relation.doi10.2147/OPTH.S91402
dc.description.reviewstatushttp://purl.org/eprint/status/PeerReviewed
dc.format.pagerange445-454
dc.relation.issn1177-5483
dc.relation.issue10
dc.rights.accesslevelopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record